Background: Opportunistic invasive fungal infections (IFIs) comprise a heterogeneous spectrum of pathogens, whose early diagnosis remains challenging. Candida spp. and Aspergillus spp, the most frequent pathogens in immunocompromised patients, frequently affect lungs, liver, bone and skin. Aim: To evaluate the impact of
Introduction
Opportunistic invasive fungal infections (IFI) comprise a widely heterogeneous and atypical spectrum of infections involving multiple pathogens capable of affecting almost all systems and organs. Hematological malignancies, stem cell or solid organ transplantation, long-term immunosuppressive treatment and uncontrolled severe diabetes mellitus are important predisposing factors for IFI development. [1] [2] [3] Among immunocompromised patients, IFI are a major cause of morbidity and death. One of the most involved pathogen, Candida spp., affects 250 000 people worldwide and is responsible for more than 50 000 deaths, with an incidence rate reported between 2 and 14 cases per 100 000 persons. 4 Candida is often responsible for fungemia and also affects liver, spleen, bone or skin. 5 Another main pathogen involved in IFI is
Aspergillus spp., especially in allogeneic stem cell transplant recipients, with an incidence rate reported between 7.3 and 15%, 6, 7 preferentially affecting lungs and sinuses. 5 In clinical practice, making the diagnosis of IFI requires patient's clinical background, physical examination, routine blood tests and microbiological analyses. The latter analyses support IFI diagnosis by showing the presence of pathogens in targeted biological samples or identifying specific fungal biomarkers. 8 PCR-based amplification techniques for molecular detection of fungal nucleic acids have also been developed. 9 When achievable, organ biopsy is considered as the gold standard for IFI diagnosis. 10 However, the isolation of the fungal pathogen does not always mean pathogenicity, particularly in non-sterile sites. Ideally, precise disease extension is required before the initiation of anti-fungal treatment, knowing that delayed anti-fungal treatment could have a deleterious impact on the patient's prognosis. Generally, long-term treatment (eventually associated to surgical procedures) is required to completely eradicate infection and to reduce the incidence of relapse. IFI treatment mostly consists in the administration of systemic anti-fungal drugs such as echinocandins, broad-spectrum triazoles, or amphotericin B formulations considering as decision-making factors the type of microorganism, site of infection, extent of disease and severity of patient immunosuppression. [11] [12] [13] Conventional imaging such as contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are usually associated with microbiological investigations to establish early diagnosis of IFI. 18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG) positron emission tomography coupled with multidetector computed tomography (PET/CT) is a non-invasive imaging technique whose role in detecting infections and systemic inflammatory diseases is widely acknowledged. [14] [15] [16] When rapidly available, 18 F-FDG PET/CT could modify the diagnostic work-up and therapeutic strategy by identifying the presence and sites of infection, determining the extent of the infection, targeting diagnostic procedures, or modulating the duration of treatment. [17] [18] [19] [20] In most studies, patients with IFI account for only a subset of the overall population investigated for FUO, hematological malignancies, or complications after solid organ transplantation. including a head to midthigh non-contrast enhanced CT, followed by a PET scan (3-5 min/field). In selected patients, PET/CT acquisitions (1-3 min/field) were performed on the lower limbs. PET data were reconstructed with and without CT-based attenuation correction by common iterative algorithm OSEM. CT, PET (corrected) and combined PET/CT images were displayed on a dedicated workstation and analysed by an experienced nuclear medicine physician aware of the patients' clinical and biological background. Patient clinical situation and previous history, as well as the CT component of PET/CT scan were considered for the assessment and interpretation of increased extraphysiologic uptake of 18 F-FDG, particularly in patients with lung disease. The standardized uptake value (SUV) was considered for semiquantitative analysis of 18 F-FDG uptake. SUV max was defined within a spherical volume of interest centered on the lesion and including it completely.
Materials and methods

Patient data
The analysis of response to treatment on follow-up 18 F-FDG PET/CTs was performed according to both visual and semiquantitative analysis. Visual response was scored using a 2-point scale: complete response (no residual abnormal uptake), and partial response (at least 1 residual site of 18 F-FDG uptake of intensity less than first examination). To assess residual infectious disease according to semi-quantitative analysis (SUV max -based response) between two consecutive 18 F-FDG PET/CTs, deltaSUV% was calculated as follows: [(PET1 SUV max -PET2 SUV max )/PET1 SUV max ] Â 100, empirically based on approved criteria for diffuse large B-cell lymphoma response assessment. 24 18 F-FDG PET/CT scans during patient follow-up were performed on the same PET/CT device. 18 F-FDG PET/CT was considered contributory when it fulfilled at least one of the following criteria: (i) identification of the presence and site of infection (other conventional tests performed at the time of PET/CT imaging were negative and/or non-contributory), (ii) determination of the extent of the infection in a specific organ or the involvement of other organs, (iii) targeting the diagnostic procedure, (iv) removal of the infection site and (v) change in the duration of anti-biotic therapy. 18 
Statistical analysis
The results are expressed as mean and standard deviation, range and percentage. Diagnostic performance of 18 F-FDG PET/ CT was evaluated according to both patient-and organ-based analysis. Hence, 18 F-FDG PET/CT sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and overall accuracy were assessed. All statistical analyses were performed using SPSS 17.0 software.
Results
Patient population
Fifty-one patients with IFI diagnosis were retrospectively included in the present study. There were 34 men (67%), with a mean age of 52 years (range: 2-84 years), including 5 pediatric patients (mean age of 6.6 years). Eight patients had active hematological malignancy; 19 patients had a recent history of hematopoietic stem cell transplantation; 16 patients had a history of solid organ transplantation; 5 patients received long-term immunosuppressive medication other than posttransplantation therapy and the remaining 3 patients suffered from uncontrolled diabetes mellitus with major complications. The 51 patients underwent a total of 83 18 F-FDG PET/CT examinations ( Figure 1 ). Twenty-nine 18 F-FDG PET/CTs were performed for IFI primary staging work-up in 29 patients, who received no previous anti-fungal treatment. The remaining 54 examinations were done during follow-up in 22 IFI patients.
At the time 18 F-FDG PET/CT was done, the mean serum C-reactive protein (CRP) level was 65 mg/l, ranging from less than 4-302 mg/l (normal value, <4 mg/l). Nineteen 18 F-FDG PET/ CTs were performed for patients who presented with persistent and unexplained inflammatory syndrome or FUO (persistent fever, for more than 96 h, unresponsive to broad-spectrum antibiotic therapy); nine for patients with neutropenia (absolute neutrophil count less than 1000/ll) with or without fever; ten for patients with dyspnea, hemoptysis and/or chronic cough; two for patients with multiple skin nodules; one for a patient with diarrhea, vomiting and abdominal pain and four with epistaxis (associated with persistent inflammatory syndrome), seizure, sub-cutaneous abscess and a swollen knee. Nine additional 18 F-FDG PET/CTs were done because of IFI suspicion, according to clinical symptomatology and/or conventional imaging results. Finally, 29 18 F-FDG PET/CTs were performed systematically in patients already treated.
Histological analysis and microbiological tests on tissue biopsy were achieved for 22 patients (43%). In the remaining 29 cases, a fungal pathogen was isolated from blood, bronchoalveolar lavage (BAL), cerebrospinal fluid and/or joint fluid samples. In the whole population, a widely heterogeneous range of microorganisms was identified. Aspergillus spp. and Candida spp. were the most frequently isolated pathogens, responsible for IFI in 23 and 17 patients, respectively. Other microorganisms responsible for IFI were Cryptococcus neoformans (five patients), Mucorales (two patients), Histoplasma capsulatum, Trichosporon asahii, Fusarium solani and Penicillium marneffei (four patients). Simultaneous multiple fungal pathogen infection was revealed in four patients, also involving Scedosporium prolificans and Scopulariopsis brevicaulis. Fungal infections sites included lung, liver, bone, pleura, sinuses, spleen, kidney, myocardium, pericardium, peritoneum, esophagus, small and large bowel, colon, rectum, brain parenchyma, meninges, aorta, lymph nodes, intervertebral disk and joints. Moreover, fungemia without any organ involvement was present in three cases.
F-FDG PET/CT results in overall population
Eighty-three 18 F-FDG PET/CTs were done in 51 patients. Overall, 18 F-FDG PET/CT global accuracy was 90%. Results of PET/CT investigations obtained in the whole population, and in cases with Candida spp. or Aspergillus spp. infections, are listed in Table 1 . Finally, details concerning specific organ involvement are reported in Table 2 . Positive 18 F-FDG PET/CT results were obtained in 33 patients (65%) and among them, 62 and three were considered as TP and FP results, respectively. On the other hand, among the 18 negative 18 F-FDG PET/CTs, 13 and 5 were TN and FN, respectively. Mean SUV max for the 62 TP 18 F-FDG PET/CT studies was 7.5 6 4.9 (range, 1-25). Detailed SUV max values according to per organbased analysis are reported in Table 2 . False positive results were due to lung cancer in two patients with lung aspergillosis who underwent PET/CT for treatment efficacy evaluation. In F-FDG PET/CT was superior to conventional imaging, including 9 CT and 1 MRI. PET/CT more accurately defined disease extension in the same organ for three patients (liver, lung, muscle); PET/CT identified infectious involvement of more organs in seven patients (bone in 2 cases, lung in 2 cases, aorta in 1 case, muscle in 2 cases, liver in 1 case, spleen in 3 cases). Moreover, in 8 out of 10 patients with Candida spp, 18 F-FDG PET/CT revealed occult infectious involvement of other organs as muscle, bone, skin, aorta wall, liver and spleen. Finally, 18 F-FDG PET/CT failed to detect brain involvement in one patient with Aspergillus spp. infection, successfully revealed by MRI.
Follow-up evaluation
Twenty-two patients with IFI underwent 54 18 F-FDG PET/CT examinations during follow-up (Figure 1 ). Among the 42 interim 18 F-FDG PET/CT examinations, one was FP (lung cancer) and two were FN (Candida spp-related knee arthritis and fungemia without organ involvement). Of the nine 18 F-FDG PET/CT examinations done to assess complete remission, two were FP related to lung cancer. Finally, one out of four 18 F-FDG PET/CT examinations done for IFI relapse was FN and related to lung aspergillosis relapse.
To assess residual infectious disease, 16 patients with TP initial examination underwent at least two 18 F-FDG PET/CT studies ( Table 3 ). The mean time interval between two consecutive 18 F-FDG PET/CT examinations was 4.4 6 3.2 months. Eleven patients showed partial or complete metabolic remission of IFI on the second 18 F-FDG PET/CT. In these patients, the mean deltaSUV max was 68% 6 25% (range, 17-100%). On the other hand, five patients had stable or progressive disease on the second 18 F-FDG PET/CT study: mean deltaSUV max was À186% 6 À130% (range, 0 to À364%). In 17 included patients (77%), contrast-enhanced CT and MRI performed before F-FDG PET/CT failed to detect Candida-related knee arthritis after 3 months of anti-fungal treatment presenting as a few millimeters bone lesion on MRI, and pulmonary aspergillosis relapse presenting as ground glass on CT in two patients. Moreover, 18 F-FDG PET/CT was more accurate than CT to assess liver and splenic persistent disease during treatment in two cases with Candida spp IFI.
F-FDG PET/CT impact in primary diagnostic work-up and therapeutic management during follow-up
Considering the 29 examinations performed at primary staging, 18 F-FDG PET/CT was considered contributory to influence the diagnostic work-up in 55% of cases by assessing the extent of the infection in a specific organ and determining the involvement of other organs in 10 cases and targeting the diagnostic procedure in 6 patients (1 liver and 2 pleural biopsies, and bronchoalveolar lavage fluid analysis). Moreover, 18 F-FDG PET/CT provided the diagnosis of skin involvement of acute leukemia and pleural lymphoma in two patients with invasive candidiasis and aspergillosis, respectively. During patient follow-up, it is quite difficult to assess the real impact of 18 F-FDG PET/CT in a retrospective setting. In the present study, the change of patient management due to the results of In our cohort, 18 F-FDG PET/CT had high sensitivity (93%) and global accuracy (90%) for the diagnosis and management of IFI. Considering only patients with aspergillosis, 18 F-FDG PET/CT sensitivity and global accuracy were consistent with the literature, equal to 90% and 97%, respectively. 25, 26 However, according to our results, 18 F-FDG PET/CT has limited impact in patients with fungemia and normal conventional imaging investigations, failing to detect organ involvment in three patients with Candida-related fungemia. Thus, although 18 F-FDG PET/CT is recommended to investigate bacteremia, 20 more data need to assess the diagnostic value of 18 F-FDG PET/CT in patients with fungemia without suspicion of organ involvement. As previously mentioned, 18 F-FDG PET/CT contributed to the diagnostic work-up in 55% of the studied patients (Figure 2 F-FDG PET/CT in a prospective study including 30 consecutive adults and children. By analogy with our population, 26 patients were immunocompromised. In 4 out of 10 patients with chronic disseminated candidiasis, 18 F-FDG PET revealed splenic abscesses not detectable on the corresponding CT scan. Furthermore, PET/CT study performed to assess the evolution of chronic disseminated candidiasis showed the complete regression of 18 F-FDG uptake abnormalities after anti-fungal therapy in three other patients.
Evaluation of residual lesions of IFI during treatment is a major challenge in immunocompromised patients. Our data suggest that 18 F-FDG PET/CT could play a role in the course of active IFI by differentiating between responder and nonresponder patients with consequent therapeutic optimization. In 8/54 IFI patients (15%), the increase of anti-fungal drugs dosage and/or the addition of new drugs was motivated by 18 F-FDG PET/CT results during treatment. These results suggest that the correlation existing between the changes of uptake intensity and the clinical course of infection potentially permits better adjustment of medical treatment ( F-FDG PET/CT examinations had been treated with antifungals for more than 60 days prior to PET/CT. Recently, Kagna et al. 28 suggested that anti-biotic treatment does not affect 18 F-FDG PET/CT accuracy in patients with infectious processes. However, the majority of the patients studied had been treated for less than 2 weeks at the time of 18 F-FDG PET/CT. In our opinion, 18 F-FDG PET/CT should be done before starting treatment or as quickly as possible to avoid potential underestimation of disease extent.
The retrospective design, the lack of systematic histopathological proof and established 18 F-FDG PET/CT follow-up, the heterogeneous spectrum of underlying diseases and fungal agents are the main limitations of our study. In addition, five paediatric patients were included, knowing the fact that IFI may behave different in children and in adults. 29 Nevertheless, it is the largest study investigating the contribution of 18 F-FDG PET/CT in management of immunocompromised patients with IFI in daily clinical practice. Interestingly, new promising specific molecular probes for PET/CT investigations of IFI have also been suggested, but there is still some way to go before their clinical application. Petrik et al. 30 proposed gallium-68 labelled siderophores microPET imaging in rat models, which could represent an Aspergillusspecific imaging technique in the near future. Davies et al.
31
worked on a pre-clinical study with an immunoPET/MRI technique, based on a 64 Cu-labelled and humanized Aspergillus-specific mouse monoclonal anti-body.
In conclusion, we recommend the systematic utilization of 18 F-FDG PET/CT to improve the primary staging of immunocompromised patients with IFI. 18 F-FDG PET/CT seems also clinically useful during follow-up, in order to assess treatment effectiveness or to confirm suspicion of IFI relapse after achieving successful outcome. In order to optimize the therapeutic strategy in such complex clinical setting, 18 F-FDG PET/CT and conventional imaging should be integrated taking into account the clinical context and both the strengths and limitations of each diagnostic modality. A well-defined diagnostic algorithm focused on specific fungus, even specific organ, might be established in the light of a randomized comparative study. Finally, optimal timing for 18 F-FDG PET/CT investigations with respect to the therapeutic regimen needs to be investigated in prospective and large multi-centric investigations. F-FDG uptake in right inferior pulmonary lobe, both hips (black arrows) and parietal wall of thoracic and abdominal aorta (multi-focal uptake; white arrows). 
